Abstract
Psilocybin, a naturally occurring psychedelic compound, has recently emerged as a promising therapeutic agent for mental health. This Patent Highlight explores the innovative approaches to harnessing psilocybin’s potential across various contexts. These include clinical trials targeting severe psychiatric conditions, the integration of low-dose psilocybin into dietary products to promote general mental well-being, and the personalization of psilocybin dosing for optimal treatment of depression and anxiety. These advancements demonstrate psilocybin’s versatility and potential to reshape conventional mental health treatment paradigms, mainly through personalized medicine and accessible wellness applications.
Important Compound Classes
Titles
Treating Alcohol Use Disorder Using Psilocybin; Low Dose Psilocybin in Foodstuff and Microbes for Same; and 5-HT Receptor Agonist Titration
Patent Publication Numbers
US 2024/0000814 A1 (URL: https://patents.google.com/patent/US20240000814A1/en?oq=US+2024%2f0000814+A1)
US 2024/0117394 A1 (URL: https://patents.google.com/patent/US20240117394A1/en?oq=US+2024%2f0117394+A1)
US 2024/0120053 A1 (URL: https://patents.google.com/patent/US20240120053A1/en?oq=US+2024%2f0120053+A1)
Publication Dates
January 4, 2024; April 11, 2024; April 11, 2024
Priority Applications
US 18/153,140; US 17/876,134; US 18/461,776
Priority Dates
September 22, 2023; July 28, 2022; September 6, 2023
Inventors
Bogenschutz, M. (US 2024/0000814 A1); Pandya, V.; Valoir, T. (US 2024/0117394 A1); and Blumstock, J.; Tyler, W. J.; Sprouse, J. (US 2024/0120053 A1)
Assignee Companies
New York University, New York, NY, United States (US 2024/0000814 A1); ATX Pharmers LLC, Austin, TX, United States (US 2024/0117394 A1); and Diamond Therapeutics Inc., Toronto, Canada (US 2024/0120053 A1)
Disease Areas
Alcohol and psychiatric disorders
Biological Targets
5-HT receptors (serotonin receptors)
Summary
Psilocybin, a psychoactive substance found in certain species of mushrooms, has been traditionally associated with spiritual and recreational use. However, recent advances in psychopharmacology have revealed its significant potential in treating various mental health conditions. This Patent Highlight reviews three recent patents that explore diverse and innovative applications of psilocybin, ranging from high-dose therapeutic interventions in clinical settings to low-dose incorporation in everyday consumables and personalized dosing strategies for treating depression and anxiety.
Psilocybin in Clinical Trials Offers New Hope for Mental Health Treatment
The first patent application, US 20240000814 A1, delves into the use of psilocybin in clinical trials aimed at treating psychiatric or neurological disorders, including depression, anxiety, and post-traumatic stress disorder (PTSD). The mechanism of action for psilocybin involves its role as a serotonin receptor agonist, mainly targeting the 5-HT2A receptors in the brain. This receptor activation is associated with significant changes in mood, perception, and cognition, which are critical in managing mental health disorders.
The innovation described in this patent emphasizes the need to rigorously evaluate psilocybin’s safety and efficacy within controlled clinical environments. Preliminary findings from these trials suggest that psilocybin can significantly reduce symptoms of depression and anxiety, potentially due to neuroplastic changes induced by the compound. These changes are contributing to long-term therapeutic benefits, making psilocybin a promising candidate for mainstream mental health treatment. Clinical assessments using tools like the Hamilton Depression Rating Scale (HDRS) and functional imaging techniques such as fMRI are employed to monitor patient outcomes and brain activity.
Bridging Mental Health and Wellness in Low-Dose Psilocybin
In contrast to the clinical focus of high-dose psilocybin, the patent application US 20240117394 A1 explores the incorporation of low-dose psilocybin into foodstuffs. This innovative approach aims to harness the mental health benefits of psilocybin in a more accessible and socially acceptable format. Low doses of psilocybin primarily act on serotonin receptors but without triggering the hallucinogenic effects typically associated with higher doses. Instead, these low doses can subtly influence mood and cognition, providing a mild but beneficial effect on mental well-being.
The goal of this innovation is to offer a novel avenue for mental health management, making the therapeutic benefits of psilocybin available to a broader audience through everyday consumables. This approach not only makes psilocybin more accessible but also paves the way for its integration into wellness products, potentially reducing anxiety and enhancing mood on a day-to-day basis. The patent outlines various biochemical assays to monitor the stability and bioavailability of psilocybin in these food matrices, ensuring that the compound retains its efficacy when consumed in this novel form.
Optimizing Treatment for Depression and Anxiety in Personalized Psilocybin Dosing
The third patent application, US 20240120053 A1, presents a method for identifying effective doses of psilocybin tailored to individual patients, particularly for treating depression and anxiety. Psilocybin’s effectiveness varies significantly among individuals due to differences in how their bodies and brains process the compound. This patent emphasizes the importance of personalized medicine in optimizing therapeutic outcomes while minimizing the risk of adverse effects.
The method involves titrating psilocybin doses to find the most effective yet safe dosage for each patient, adjusting as needed based on ongoing assessments. The patent contains neurophysiological monitoring tools like EEG to track brain activity and psychological assessments like the Beck Depression Inventory (BDI) and Generalized Anxiety Disorder (GAD-7) scale to evaluate treatment efficacy. The findings support the potential of subhallucinogenic doses of psilocybin to induce positive changes in brain activity, correlating with improved mood and reduced symptoms of depression and anxiety.
These three patents collectively highlight the versatility and therapeutic potential of psilocybin across different contexts. From high-dose clinical interventions to low-dose wellness applications and personalized dosing strategies, psilocybin demonstrates a wide range of benefits for mental health. Each approach addresses different aspects of treatment, from managing severe mental health disorders to enhancing everyday mental well-being.
The continued research and development in this field underscore the importance of tailoring psilocybin use to individual needs through precise clinical protocols or more accessible consumer products. As these innovations progress, psilocybin could become a cornerstone in the next generation of mental health treatments, offering new hope for those struggling with depression, anxiety, and other related conditions.
As such, the advancements described in these patents represent a significant step forward in applying psilocybin to mental health. By exploring various dosages, formats, and personalized approaches, these innovations will modify how we understand and treat mental health conditions. As research continues, psilocybin may soon transition from a fringe therapeutic to a mainstream treatment option, with the potential to improve the lives of millions worldwide.
Key Structures
Biological Assay
Double blind, participants were offered 12 weeks of manualized psychotherapy and were randomly assigned to receive psilocybin vs diphenhydramine during two day-long medication sessions at week 4 and 8.
Biological Data
The table below
shows that psilocybin-treated
participants were more likely than those receiving diphenhydramine
to have no heavy drinking days and to have a 2-level reduction in
WHO risk level during weeks 5–36. During the final month of
follow-up (weeks 33–36), these differences persisted, and the
rates of abstinence as well.
Recent Review Articles
The author declares no competing financial interest.
References
- Szafoni S.; Gręblowski P.; Grabowska K.; Więckiewicz G. Unlocking the Healing Power of Psilocybin: An Overview of the Role of Psilocybin Therapy in Major Depressive Disorder, Obsessive-Compulsive Disorder and Substance Use Disorder. Front. Psychiatry 2024, 15, 1406888. 10.3389/fpsyt.2024.1406888. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Köhne S.; Hillemacher T.; Glahn A.; Bach P. Emerging Drugs in Phase II and III Clinical Development for the Treatment of Alcohol Use Disorder. Expert Opin. Emerg. Drugs 2024, 29, 219. 10.1080/14728214.2024.2342951. [DOI] [PubMed] [Google Scholar]
- Koob G. F. Alcohol Use Disorder Treatment: Problems and Solutions. Annu. Rev. Pharmacol. Toxicol. 2024, 64, 255. 10.1146/annurev-pharmtox-031323-115847. [DOI] [PubMed] [Google Scholar]
- Lodetti G.; de Bitencourt R. M.; Rico E. P. Classic Psychedelics and the Treatment for Alcoholism. Prog. Neuropsychopharmacol. Biol. Psychiatry 2024, 135, 111129. 10.1016/j.pnpbp.2024.111129. [DOI] [PubMed] [Google Scholar]
- Tap S. C. The Potential of 5-Methoxy-N,N-Dimethyltryptamine in the Treatment of Alcohol Use Disorder: A First Look at Therapeutic Mechanisms of Action. Addict. Biol. 2024, 29, e13386. 10.1111/adb.13386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sicignano D.; Hernandez A. V.; Schiff B.; Elmahy N.; White C. M. The Impact of Psychedelics on Patients with Alcohol Use Disorder: A Systematic Review with Meta-Analysis. Curr. Med. Res. Opin. 2024, 40 (2), 293–302. 10.1080/03007995.2023.2296968. [DOI] [PubMed] [Google Scholar]